Understanding how kindlin-3 affects platelet function
Official title: Kindlin-3 signaling in platelets
Funded at Versiti Wisconsin, INC. · NIH-10761763 · Data updated 2026-11-12
This study is looking at how a protein called kindlin-3 helps activate another protein in platelets that is important for blood clotting, with the goal of finding new ways to prevent dangerous blood clots, which could help patients with certain blood disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | February 10, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $579,860 |
| NIH project number | 5R01HL157309-03 |
| Project ID | NIH-10761763 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cardiovascular disorders or conditions related to platelet dysfunction.
✕Less likely to help
Patients with non-cardiovascular conditions or those without platelet-related issues may not benefit from this research.
What this research studies
This research investigates the role of kindlin-3 in the activation of a specific protein in platelets called integrin αIIbβ3, which is crucial for blood clotting. By examining how kindlin-3 influences platelet behavior, the research aims to find ways to control excessive platelet accumulation that can lead to dangerous blood clots. The study involves analyzing the interactions between kindlin-3 and integrin proteins in platelets, which may help in developing new treatments for cardiovascular diseases. Patients with certain blood disorders may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent dangerous blood clots in patients with cardiovascular diseases.
How similar studies have gone: Previous research has shown that targeting integrin activation can lead to significant advancements in treating blood clotting disorders, indicating a promising avenue for this investigation.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Ma, Yan-Qing — Versiti Wisconsin, INC.
- Study coordinator: Ma, Yan-Qing
Related research
Other NIH-funded projects on the same topics.
-
Improving blood safety and availability for transfusions in children and adults
This study is looking to make blood transfusions safer and more accessible for both kids and adults by gathering information from blood donors and recipients across the US and Brazil, so that everyone can benefit from better transfusion practices in the future.
-
Understanding how to safely increase fetal hemoglobin for treating blood disorders
This study is looking at how to safely boost fetal hemoglobin levels in people with blood disorders like beta-thalassemia, by exploring new ways to change certain cells in the body, so that patients can have better treatment options.
-
Understanding how certain proteins regulate blood clotting and cardiovascular diseases
This study is looking at how two proteins that help with blood clotting and heart health work, which could lead to better treatments for blood clotting disorders and heart disease.
-
Targeting a specific gene to treat a type of leukemia
This study is testing a new treatment called AI-10-49 for people with acute myeloid leukemia who have a specific genetic change that makes their condition harder to treat, and it aims to help these patients live longer by killing leukemia cells and working better with other medications.
-
Understanding maternal immune responses affecting newborns with low platelet counts
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
-
Understanding the immune response in patients with heparin-induced thrombocytopenia
This study is looking at how the immune system responds to heparin, a blood thinner, to find out more about a serious condition called heparin-induced thrombocytopenia (HIT), and it aims to help doctors better identify harmful antibodies in patients, even if their regular tests come back normal, so they can prevent ser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.